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Abstract
Background
We have previously demonstrated an association between increased sFRP3 expression
and adverse outcome in a population of HF irrespective of cause and left ventricular ejection
fraction. In this study we evaluated the prognostic value of sFRP3 in older patients with
chronic systolic HF of ischemic origin.
Methods
We evaluated sFRP3, by tertiles, as a risk factor for the primary endpoint (cardiovascular
[CV] mortality, nonfatal myocardial infarction, nonfatal stroke), all-cause mortality, CV mor-
tality, death from worsening HF (WHF), any coronary event, including sudden death, as well
as hospitalizations for CV causes and WHF in 1444 patients from the CORONA population,
randomly assigned to 10 mg rosuvastatin or placebo.
Results
Kaplan-Meier curves for the primary endpoint, as well as all-cause- and CV mortality
revealed a markedly better survival for patients with sFRP3 levels in the middle tertile of
compared to the 1st and 3rd tertile. In multivariable Cox-regression, after full adjustment
including high-sensitive CRP and NT-proBNP, a lower event rate for the primary end point,
all cause and CV mortality was observed for patients with tertile 2 sFRP3 levels (HR 0.57
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[0.44–0.74], 0.55 [0.44–0.74] and 0.52 [0.39–0.69]; p<0.001), as well as for the number of
coronary events (HR 0.62 [0.47–0.82], p = 0.001) and sudden death (HR 0.55 [0.37–0.82],
p = 0.002). Applying sFRP3 values to the fully adjusted regression model resulted in highly
significant continuous net reclassification improvements for the primary endpoint, all cause
and CV mortality, coronary events and sudden death (range 0.24–0.31; p0.002 for all).
Conclusions
Intermediate serum sFRP3 levels are associated with better survival and fewer CV events
than low or high sFRP3 levels, independently of conventional risk factors, in older patients
with chronic systolic HF of ischemic origin. Our study suggests that balanced Wnt activity
might confer protective effects in a clinical HF setting.
Trial Registration
http://www.clinicaltrials.gov NCT00206310
Introduction
The wingless (Wnt) signaling pathway regulates a multitude of essential cellular processes dur-
ing embryonic development [1] and well-orchestrated Wnt signaling is necessary for proper
heart formation [2]. Wnt activity is normally low and tightly regulated in the adult organism
[3], but when dysregulated upon pathological stress or injury, both hypo- and hyper-activity of
Wnt signaling has been associated with a wide variety of clinical diseases, including cardiovas-
cular (CV) disorders [4–8]. Secreted modulators regulate both canonical (β-catenin dependent)
and non-canonical (β-catenin independent) Wnt signaling at the surface membrane. The
secreted frizzled related proteins (sFRPs) bind directly to Wnt ligands in the extracellular
space, potentially interfering with both canonical and non-canonical Wnt pathways [9,10].
Several experimental studies have indicated beneficial effects of sFRP1 and sFRP2 on myocar-
dial remodeling [10–15], but few studies have examined the role of sFRP3 in these processes.
We recently reported increased left ventricular (LV) mRNA levels of sFRP3 and non-canonical
Wnt ligands in end-stage clinical heart failure (HF), with reversible expression patterns upon
hemodynamic unloading following LV assist device treatment [16]. In vitro, we identified
increased LV wall tension as a potential activator of sFRP3 expression and release. However, a
definitive role of sFRP3 in HF development and progression remains unconfirmed.
Secreted Wnt modulators (e.g. sFRP3) are measurable in the systemic circulation and ele-
vated serum and plasma levels have been associated with disease progression and response to
therapy in both atherosclerosis and malignant disease [7,17,18]. In a recent report we found an
association between serum sFRP3 levels and mortality in a large HF population of mixed etiol-
ogy, i.e. the GISSI-HF-HF trial [16]. In the present study we investigated the prognostic signifi-
cance of circulating sFRP3 in patients with chronic systolic HF population of purely ischemic
etiology, i.e. a sub-study of patients enrolled in the Controlled Rosuvastatin Multinational Trial
in HF (CORONA) [19].
sFRP3 in Chronic Heart Failure
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Methods
Patients and Study Procedures
Clinical trials identifier: NCT00206310. The trial complied with the Declaration of Helsinki
and was approved by the Ethics Committees of the participating hospitals. All patients pro-
vided written informed consent. Ethics committee/institutional review board: Regional Etik-
sprövningskommitten I Göteborg, Sahlgrenska Akademin, Mediniargatan 3, Plan 5. Diary
number: Ö284-03.
The name of the ethics committees from any of the participating hospitals (378) can be pro-
vided on request. Name of study locations are added at the bottom. The design and principal
findings of CORONA have been reported in detail [19]. Briefly, patients60 years of age with
chronic HF attributed to ischemic heart disease, defined as (i) medical history or ECG signs of
myocardial infarction (MI) or (ii) other data suggesting an ischemic etiology (e.g. wall motion
disturbances on echocardiography or history of other occlusive atherosclerotic disease [i.e. ear-
lier stroke, intermittent claudication, percutaneous coronary intervention (PCI)]), who were in
New York Heart Association (NYHA) class II-IV, with a LV ejection fraction (LVEF)40%
(35% if NYHA II), were eligible for inclusion. All patients provided written informed con-
sent. Patients (n = 1444) were randomly assigned to rosuvastatin 10 mg/day (n = 727) or
matching placebo (n = 717), once-daily. The present study was an optional, predefined sub-
study of the main CORONA trial which included patients from centers capable of collecting
the necessary blood samples. Although in general similar to the main CORONA study, there
were some modest statistical differences in the baseline characteristics between this sub-study
and the complete study population as reported previously [20].
Study outcomes and definitions
The primary predefined outcome was the composite of death from CV causes, non-fatal MI,
and non-fatal stroke, analyzed as time to the first event. The secondary predefined outcomes
were a) all-cause mortality, b) CV mortality (including cause-specific CV death), c) any coro-
nary event (defined as sudden death, fatal or non-fatal MI, performance of PCI or coronary
artery bypass graft surgery [CABG], ventricular defibrillation by an implantable cardioverter-
defibrillator [ICD], resuscitation from cardiac arrest, or hospitalization for unstable angina
pectoris), d) the number of hospitalizations for CV causes, and e) hospitalization for worsening
HF (WHF). The definition and adjudication of all outcomes have been described in detail pre-
viously, as have data on C-reactive protein (CRP) and N-terminal pro-B-type natriuretic pep-
tide (NT-proBNP) [19,21–23].
Blood sampling and biochemical analyses
sFRP3 was measured from blood samples taken after an overnight fast. All other blood samples
were non-fasting and analyzed on fresh samples at a central laboratory (Medical Research Lab-
oratories, Zaventem, Belgium). NT-proBNP was analyzed using commercially available assay
(Roche Diagnostics, Basel, Switzerland). An immunonephelometric high-sensitivity method
was used to measure CRP (Dade Behring, Atterbury, UK; sensitivity 0.04 mg/L). Serum sFRP3
was measured by enzyme immunoassay (R&D Systems, Minneapolis, MN) as validated previ-
ously [16].
Statistical analysis
For all baseline variables, differences between middle-tertile sFRP3 values and the combination
of the highest- and lowest tertile were tested with Student’s t-test for normally distributed
sFRP3 in Chronic Heart Failure
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variables, Fisher’s exact test for categorical data, and Wilcoxon rank-sum test for non-normally
distributed variables. Trends over sFRP3 tertiles were tested with the Cuzick extension of the
Wilcoxon rank-sum test, and all baseline variables with a p-value for trend<0.05 were
included in a multivariable analysis to identify degree of association with sFRP3. All survival
analyses were conducted using the Cox proportional hazard regression model. A restricted
cubic spline (RCS) analysis with three knots was undertaken on the outcome all-cause mortal-
ity to assess linearity of risk. The RCS analysis revealed a U-shaped curve with lower risk for
patients in the middle tertile of sFRP3 concentration corresponding approximately to the pat-
tern seen in Kaplan-Meier plots for all-cause and CVmortality. Therefore, in multivariate anal-
yses, sFRP3 was included as a categorical (by tertiles) variable to a version of the three stage
model described elsewhere [23], which included mainly clinical variables at step one (LVEF,
NYHA class, age, body mass index [BMI], diabetes mellitus [DM], sex, intermittent claudica-
tion, and heart rate [HR]). At step two, estimated glomerular filtration rate (eGFR) and apoli-
poprotein (Apo) B/ApoA-1 ratio were included in the model, and finally, at stage 3, the log-
transformed serum concentrations of NT-proBNP and CRP were included. Harrel’s C-statistic
was calculated for all endpoints using the full model with and without sFRP3, and the differ-
ence between the C-statistics was estimated. We implemented a jack-knife cross-validation
approach to correct for over-optimism associated with validating a model in the same material
from which it is developed. In this approach predictions for each observation were obtained
from models developed on the remaining observations. These cross-validated probabilities
were used to calculate jack-knife C-statistics. Calculation of the net reclassification improve-
ment (NRI) is increasingly being used to evaluate the prognostic usefulness of a biomarker
[24]. When no established risk categories exist, the use of a category-free NRI has been advo-
cated [25]. We therefore calculated the category-free NRI after adding sFRP3 to the full model.
Confidence intervals and p-values for NRI were determined by boot-strapping with 2000 repe-
titions. A two-sided p-value<0.05 was considered to be significant, except for interaction
terms, for which p-values<0.10 were accepted. All statistical analyses were performed using
STATA version 11 for Windows (StataCorp, College Station, TX). The authors had full access
to and take responsibility for the integrity of the data. All authors have read and agreed to the
manuscript as written.
Results
Serum concentrations of sFRP3 were measured at baseline in 1444 patients. Patient character-
istics according to tertile values of sFRP3 are shown in Table 1. Patients in the top tertile of
sFRP3 were more likely to be in atrial fibrillation (AF), take digoxin and had more frequent
intermittent claudication. They also had higher NT-proBNP, more use of diuretics and aldoste-
rone antagonists and had slightly worse NYHA functional classification. In addition patients in
the top tertile smoked less, had lower total cholesterol levels and lower renal function. Patients
in the middle sFRP3 tertile had higher LVEF and significantly lower CRP levels than patients
in the top and bottom tertiles. LVEF and CRP were the only variables associated with having
sFRP3 in the second tertile in a logistic regression analysis, but with very modest correlation
coefficients (r = 0.02, p = 0.034 and r = 0.12, p = 0.012 respectively).
sFRP3 levels and association with outcomes
During a median follow-up of 955 (inter-quartile range 817–1103) days, 421 patients died.
Kaplan-Meier plots for the primary end point, as well as for all-cause and CV mortality
revealed a markedly poorer outcome for patients in the highest and lowest tertile of sFRP3 con-
centration compared to the middle tertile (Fig 1). A restricted cubic spline analysis confirmed
sFRP3 in Chronic Heart Failure
PLOS ONE | DOI:10.1371/journal.pone.0133970 August 19, 2015 4 / 13
Table 1. Clinical and biochemical baseline characteristics stratified by tertile values of sFRP3.
Variable Total population sFRP3 tertile 1st tertile 2nd tertile 3rd P-value Trend P-value2nd
Age, years 71.8±6.9 71.8±7.1 71.7±6.7 72.0±6.7 0.587 0.583
Female sex 338 (23.4) 118 (24.5) 102 (21.2) 118 (24.5) 0.986 0.167
NYHA class 0.015 0.560
II 464 (32.1) 174 (36.1) 149 (31.0) 141 (29.3)
III 963 (66.7) 304 (63.1) 328 (68.2) 331 (68.8)
IV 17 (1.2) 4 (0.8) 4 (0.8) 9 (1.9)
Ejection Fraction 0.32±0.07 0.31±0.07 0.32±0.06 0.31±0.07 0.846 0.017
BMI, kg/m2 27.2±4.6 27.2±4.8 27.3±4.4 27.3±4.5 0.970 0.764
SBP, mmHg 129±16 130±17 130±15 129±16 0.221 0.548
DBP, mmHg 77±9 77±9 77±9 77±9 0.792 0.488
Heart rate, b.p.m 70.9±10.8 70.5±10.1 71.1±11.1 71.1±11.2 0.561 0.626
Smoking 175 (12.1) 82 (17.0) 50 (10.4) 43 (8.9) 0.000 0.171
Treatment n = (rosuvastatin/placebo) 727/717 237/245 235/246 245/236 0.785 0.669
Medical history
Myocardial infarction 909 (63.0) 307 (63.7) 318 (66.1) 284 (59.0) 0.136 0.083
Angina pectoris 1065 (73.8) 363 (75.3) 352 (73.2) 350 (72.8) 0.369 0.751
Other atherosclerotic disease 287 (19.9) 90 (18.7) 94 (19.5) 103 (21.4) 0.287 0.834
PCI or CABG 300 (20.8) 93 (19.3) 108 (22.5) 99 (20.6) 0.622 0.271
Hypertension 1000 (69.3) 323 (67.0) 337 (70.1) 340 (70.7) 0.217 0.672
Diabetes Mellitus 378 (26.2) 126 (26.1) 138 (28.7) 114 (23.7) 0.390 0.128
Atrial Fibrillation/Flutter 321 (22.2) 81 (16.8) 107 (22.2) 133 (27.7) <0.001 1.000
Stroke 173 (12.0) 65 (13.5) 53 (11.0) 55 (11.4) 0.327 0.441
Intermittent Claudication 154 (10.7) 43 (8.9) 49 (10.2) 62 (12.9) 0.046 0.718
Laboratory measurements
Total cholesterol, mmol/L 5.23±1.09 5.34±1.13 5.17±0.99 5.17±1.15 0.041 0.170
LDL, mmol/L 3.65±0.97 3.71±0.99 3.59±0.99 3.64±0.94 0.286 0.133
HDL, mmol/L 1.23±0.34 1.26±0.36 1.22±0.33 1.22±0.34 0.108 0.477
Triglycerides, mmol/L 2.01±1.40 2.06±1.51 1.95±1.26 2.02±1.41 0.855 0.239
Apo B/Apo A-1 value 0.89±0.25 0.89±0.25 0.87±0.24 0.90±0.26 0.494 0.158
eGFRMDRD (mL/min/1.73 m
2) 57.4±14.3 58.1±14.6 58.0±13.9 56.2±14.3 0.057 0.270
NT-pro-BNP, pmol/L 162 (61–344) 141 (53–322) 164 (64–330) 187 (74–420) 0.005 0.959
CRP, mg/L 3.7 (1.6–7.7) 3.6 (1.6–7.9) 3.2 (1.5–6.8) 4.4 (1.9–8.0) 0.152 0.007
sFRP3, pg/mL 1190 (853–1760) 729 (30–962) 1191 (963–1524) 2149 (1525–2530) 0.000 0.000
Medication
Diuretics 0.006 0.249
Loop or Thiazide 1099 (76.1) 369 (76.6) 354 (73.6) 376 (78.2)
Both 157 (10.9) 40 (8.3) 60 (12.5) 57 (11.9)
Aldosterone antagonist 527 (36.5) 161 (33.4) 174 (36.2) 192 (39.9) 0.036 0.862
ACE inhibitor 1162 (80.5) 388 (80.5) 387 (80.5) 387 (80.5) 0.987 1.000
ARB 147 (10.2) 53 (11.0) 48 (10.0) 46 (9.6) 0.462 0.926
Beta blocker 1100 (76.2) 357 (74.1) 369 (76.7) 374 (77.8) 0.179 0.744
Digitalis glycoside 416 (28.8) 119 (24.7) 140 (29.1) 157 (32.6) 0.006 0.902
NT-proBNP and CRP are displayed as median value (interquartile range). Other variables are shown as number (percentage of total) or as mean
(standard deviation) where appropriate. P-value Trend, p-value for trend across all tertiles; P-value 2nd, p-value for 2nd tertile compared to 1st and 3rd tertile
combined.NYHA, New York Heart Association; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PCI, percutaneous
coronary intervention; CABG, coronary artery bypass grafting; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ApoB, apolipoprotein B; ApoA-1,
apolipoprotein A-1; eGFR, estimated glomerular ﬁltration rate; MDRD, modiﬁcation of diet in renal disease; CRP, C-reactive protein; NT-proBNP, amino-
terminal pro-brain natriuretic peptide; sFRP3, secreted frizzled related protein 3; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor
blocker.
doi:10.1371/journal.pone.0133970.t001
sFRP3 in Chronic Heart Failure
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non-linearity of risk, with a U-shaped curve corresponding approximately to a tertile division
of the patient population. Subsequent analyses were therefore undertaken on sFRP3 tertiles.
Unadjusted Cox proportional hazard regression models displayed significant associations
between baseline sFRP3 levels and the primary endpoint, all-cause and CV mortality, sudden
death and coronary events (Table 2). The hazard ratios varied from 0.76 for coronary events to
0.64 for death from CV causes. Baseline sFRP3 was not associated with death fromWHF or
hospitalizations, irrespective of cause (Table 2).
When adjusting for demographic variables (step 1) in a three step multivariable analysis,
sFRP3 was still associated with the primary endpoint, all-cause mortality, death due to CV
cause, sudden death and coronary events (Table 2). These associations remained significant
after adjusting for ApoB/ApoA-1 ratio and eGFR (step 2). When correcting for NT-proBNP
and CRP (step 3), sFRP3 remained a strong predictor for the primary endpoint, overall mortal-
ity, death from CV cause, sudden death and coronary events, with little change in hazard ratios
from the unadjusted model (Table 2). As seen in Table 3, addition of sFRP3 in the multivari-
able analyses did not alter the effects of other variables, suggesting incremental value of sFRP3
and a non-competing relation to conventional risk factors. This finding is further underscored
by highly significant continuous net reclassification improvements (NRI) for the primary end-
point (NRI 0.26, p<0.0001), all-cause mortality (NRI 0.28, p<0.000001), death from CV cause
(NRI 0.31, p<0.000001), as well as for coronary events (NRI 0.24, p<0.0001) and sudden
death (NRI 0.25, p = 0.002) when sFRP3 was added to the fully adjusted models (Table 2).
However, the isolated discriminatory properties of sFRP3 were limited (Table 4), indicating
that sFRP3 measurements, at present, are mostly of interest in multi-marker risk models and
from a mechanistic point of view.
Comparison with the GISSI-HF-HF trial
These finding are in contrast to a recent study from our group demonstrating a linear increase
in risk for outcome in 1202 HF patients with mixed etiology from the GISSI-HF-HF trial [16].
When evaluating the association between sFRP3 and outcome in patients with ischemic etiol-
ogy in the GISSI-HF trial, a similar association was observed in patients<70 years of age with
ischemic etiology (n = 345, Fig 2A), as when all patients in GISSI-HF with both etiologies were
included. However, when looking at patients>70 years of age with ischemic etiology (n = 261),
no association was observed (Fig 2B), in contrast to non-ischemic patients aged>70 years
Fig 1. Kaplan-Meier curves for the primary end point (panel A), as well as for all-cause (B) and CV (C) mortality according to tertile sFRP3
concentration. T1, lowest tertile serum sFRP3; T3, highest tertile serum sFRP3. Patients with T2 sFRP3 showed a markedly better outcome than patients in
T1 and T2; p<0.001 for the primary end point and all-cause mortality, p<0.002 for CV mortality.
doi:10.1371/journal.pone.0133970.g001
sFRP3 in Chronic Heart Failure
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Table 2. Multivariable analysis of intermediate levels of sFRP3 as a predictor of outcome.
sFRP3 Events HR (95% CI) p-value Wald C index, Δ NRI
Primary end point -0.012 (0.034) 0.26 (<0.001)
Unadjusted 406 0.66 (0.53–0.82) <0.001 13.50
Step 1 406 0.65 (0.52–0.81) <0.001 14.50
Step 2 404 0.66 (0.53–0.82) <0.001 13.40
Step 3 315 0.57 (0.44–0.74) <0.001 18.60
All-cause mortality -0.0096 (0.055) 0.28 (<0.001)
Unadjusted 421 0.66 (0.53–0.82) <0.001 14.20
Step 1 421 0.65 (0.52–0.81) <0.001 15.00
Step 2 418 0.65 (0.52–0.82) <0.001 14.20
Step 3 327 0.55 (0.42–0.71) <0.001 21.40
CV mortality -0.012 (0.045) 0.31 (<0.001)
Unadjusted 342 0.64 (0.51–0.82) <0.001 12.70
Step 1 342 0.64 (0.51–0.82) <0.001 12.70
Step 2 340 0.65 (0.51–0.83) 0.001 11.60
Step 3 264 0.52 (0.39–0.69) <0.001 19.90
Death from WHF -0.0045 (0.44) 0.17 (0.42)
Unadjusted 104 0.72 (0.47–1.10) 0.127 2.32
Step 1 104 0.72 (0.47–1.11) 0.140 2.18
Step 2 104 0.73 (0.47–1.12) 0.149 2.08
Step 3 80 0.59 (0.36–0.99) 0.045 4.02
Sudden death -0.0066 (0.40) 0.25 (0.002)
Unadjusted 191 0.69 (0.51–0.96) 0.025 5.01
Step 1 191 0.69 (0.50–0.95) 0.022 5.21
Step 2 189 0.70 (0.51–0.97) 0.030 4.71
Step 3 149 0.55 (0.37–0.80) 0.002 9.89
Coronary end point -0.0060 (0.37) 0.24 (<0.001)
Unadjusted 326 0.76 (0.55–0.90) 0.005 7.88
Step 1 326 0.71 (0.55–0.90) 0.005 7.84
Step 2 322 0.71 (0.55–0.91) 0.006 7.52
Step 3 254 0.62 (0.47–0.82) 0.001 11.4
Hospitalization, any cause 0.00082 (0.10) 0.018 (0.73)
Unadjusted 814 0.91 (0.79–1.05) 0.205 1.60
Step 1 812 0.91 (0.79–1.06) 0.225 1.78
Step 2 805 0.91 (0.78–1.05) 0.183 1.78
Step 3 655 0.96 (0.81–1.13) 0.623 0.24
Hospitalization, CV cause 0.00083 (<0.001) 0.028 (0.58)
Unadjusted 613 0.95 (0.80–1.12) 0.523 0.41
Step 1 611 0.95 (0.81–1.13) 0.595 0.28
Step 2 606 0.95 (0.80–1.13) 0.565 0.33
Step 3 499 0.99 (0.82–1.19) 0.877 0.02
Hospitalization from WHF 0.00074 (0.33) 0.042 (0.47)
Unadjusted 334 0.97 (0.78–1.22) 0.816 0.054
Step 1 333 0.97 (0.77–1.21) 0.769 0.086
Step 2 331 0.95 (0.75–1.19) 0.639 0.22
Step 3 275 0.93 (0.73–1.20) 0.601 0.27
Death or hospitalization from WHF 0.00081 (0.53) 0.089 (0.21)
Unadjusted 371 0.93 (0.75–1.16) 0.528 0.40
(Continued)
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(n = 215, Fig 2C). In addition, when applying the tertile limits derived from the GISSI-HF pop-
ulation on the CORONA population we found a similar stepwise association with outcome (i.e.
all-cause and CV mortality) as observed in GISSI-HF, although weaker (Fig 2D).
Effect of rosuvastatin treatment on sFRP3 levels and clinical outcomes
Serum sFRP3 concentrations were similar at baseline and three month follow up (continuous
variable) both in patients assigned to placebo (n = 717) or rosuvastatin (n = 727). An interac-
tion of sFRP3 and treatment group was not observed for any endpoints.
Discussion
In this post-hoc analysis from CORONA we found serum concentrations of sFRP3 to be asso-
ciated with fatal outcomes in a large population of elderly patients with chronic systolic HF of
Table 2. (Continued)
sFRP3 Events HR (95% CI) p-value Wald C index, Δ NRI
Step 1 370 0.93 (0.75–1.15) 0.498 0.46
Step 2 368 0.91 (0.73–1.13) 0.401 0.71
Step 3 300 0.90 (0.71–1.15) 0.410 0.68
sFRP3, 2nd tertile vs. 1st and 3rd tertile, as predictor of outcome. All Hazard Ratios (HR) are given as HR (95% conﬁdence interval). C index, Δ; difference
in C index between fully adjusted model with and without inclusion of sFRP3, corresponding (p-value). Net Reclassiﬁcation Improvement (NRI); calculated
from C-indexes for fully adjusted models with and without inclusion of sFRP3, corresponding (p-value). Unadjusted (n = 1444). The models are adjusted
as follows: Step 1 (n = 1441): Ejection fraction, New York Heart Association functional class, age, body mass index, diabetes mellitus, sex, intermittent
claudication and heart rate. Step 2 (n = 1428): All variables from Step 1 as well as ApoB/Apo A-1 ratio and estimated glomerular ﬁltration rate. Step 3
(1194): all variables from Step 2 as well as C-reactive protein and amino-terminal pro B-type natriuretic peptide. CV, cardiovascular; WHF, worsening
heart failure.
doi:10.1371/journal.pone.0133970.t002
Table 3. Effect of sFRP3 on the association between other predictors and outcome.
All-cause Mortality CV Mortality
Variable Without sFRP3 With sFRP3 Without sFRP3 With sFRP3
Ejection fraction (x 100) HR 1.00 (0.98–1.02) 1.00 (0.98–1.02) 1.00 (0.98–1.02) 1.00 (0.98–1.02)
Age (x 10) HR 1.21 (0.94–1.34) 1.14 (0.95–1.36) 1.09 (0.89–1.33) 1.11 (0.91–1.35)
Heart rate (x 1/10) HR 1.06 (0.96–1.17) 1.07 (0.96–1.18) 1.05 (0.93–1.17) 1.05 (0.94–1.18)
Female sex HR 0.72 (0.54–0.97) 0.69 (0.52–0.92) 0.73 (0.57–1.07) 0.75 (0.55–1.03)
Diabetes Mellitus HR 1.60 (1.25–2.04) 1.61 (1.26–2.05) 1.54 (1.18–2.02) 1.55 (1.18–2.03)
Intermittent Claudication HR 1.46 (1.08–1.99) 1.49 (1.09–2.02) 1.31 (0.92–1.87) 1.34 (0.94–1.92)
BMI HR 0.95 (0.93–0.98) 0.95 (0.93–0.98) 0.96 (0.93–0.99) 0.96 (0.93–0.99)
NYHA III HR 1.15 (0.88–1.49) 1.11 (0.85–1.44) 1.12 (0.83–1.49) 1.07 (0.80–1.44)
NYHA IV HR 1.53 (0.75–3.14) 1.37 (0.66–2.84) 1.52 (0.71–3.28) 1.34 (0.61–2.92)
eGFR HR 0.99 (0.98–1.00) 0.99 (0.98–1.00) 0.99 (0.98–1.00) 0.99 (0.98–1.00)
Apo B/Apo A-1 ratio HR 1.06 (0.67–1.68) 1.04 (0.65–1.64) 1.22 (0.74–2.02) 1.20 (0.72–1.98)
NT-proBNP HR 1.62 (1.45–1.82) 1.63 (1.46–1.83) 1.76 (1.55–2.00) 1.78 (1.56–2.01)
CRP HR 1.19 (1.09–1.31) 1.18 (1.07–1.30) 1.16 (1.04–1.28) 1.14 (1.03–1.27)
T2 sFRP3 HR 0.55 (0.42–0.71) 0.52 (0.39–0.69)
BMI, body mass index; NYHA, New York Heart Association; eGFR, estimated glomerular ﬁltration rate; ApoB, apolipoprotein B; ApoA-1, apolipoprotein A-
1; NT-proBNP, amino-terminal pro-brain natriuretic peptide; CRP, C-reactive protein; T2 sFRP3, middle tertile secreted frizzled related protein 3.
doi:10.1371/journal.pone.0133970.t003
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ischemic origin, with a significantly worse prognosis for patients in the first and third tertiles as
opposed to those in the second tertile. Hazard ratios attributed to mid-tertile sFRP3 values
remained significant and stable for the primary endpoint, all-cause- and CV mortality, sudden
death and coronary events also after adjusting for established risk factors, including NT-
proBNP and CRP, in a step-wise fashion. These data suggest a biphasic association between
sFRP3 and outcome in the CORONA population with high and low levels associated with a
poorer prognosis.
We have previously shown elevated sFRP3 levels in the GISSI-HF-HF population of both
ischemic and non-ischemic etiologies [16], with unfavorable prognosis associated with increas-
ing sFRP3 concentrations. Recently, Motiwala et al. assessed the predictive value of sFRP3 in
142 patients with HF [26] and found no significant association with mortality, although a
trend towards higher levels in patients with a CV event was observed (p = 0.10). Furthermore,
no survival analysis was performed and the HF populations differed markedly in size, demo-
graphics, endpoint definition and follow-up period making it difficult to compare the studies.
Compared to our finding in the GISSI-HF-HF trial [16], the current study partly contradicts
these findings by demonstrating a non-linear association between sFRP3 and outcomes in the
CORONA population. This discrepancy may partly be explained by different characteristics of
the study populations. The CORONA population had substantially lower functional capacity,
with ~70% of the patients being in NYHA III-IV compared to 26% in GISSI-HF-HF. More-
over, the CORONA study included only patients with reduced LVEF while patients with both
reduced and preserved LVEF were included in GISSI-HF-HF, and kidney function was also
lower in the CORONA cohort (eGFR 57 vs. 69 mL/min/1.73m2). The CORONA population
consisted of older patients (71.8±6.9 vs. 66.3±10.8 years in GISSI-HF-HF) with HF of ischemic
etiology, whereas the GISSI-HF-HF patients had HF of both ischemic and non-ischemic etiol-
ogy. Indeed, when evaluating mortality in the GISSI-HF-HF trial stratified by etiology and age
we found that in contrast to patients with ischemic HF<70 years who demonstrated a more
linear association between sFRP3 and outcome, this association was not present in older
patients (i.e.>70 years) with ischemic HF. Furthermore, although caution is needed when
comparing circulating sFRP3 from different populations analyzed on separate occasions,
sFRP3 levels were approximately 50% higher in GISSI-HF-HF compared to CORONA. Thus,
the first tertile of GISSI-HF and the second tertile in CORONA had comparable levels and
were associated with the best outcome, while tertile 3 in CORONA and tertile 2 and 3 in
GISSI-HF represent a further increase in adverse events. Indeed, applying the tertile limits
derived from the GISSI-HF population [16] on the CORONA population demonstrated a
similar, although weaker, stepwise association with outcome as observed in GISSI-HF.
Table 4. Discriminatory properties of sFRP3. Area under curve (AUC) and 95%Confidence interval (CI)
of sFRP3 as a categorical (1. and 3. tertile vs. 2. tertile) variable, corresponding p-value.
End point AUC CI p-value
Primary endpoint 0.55 0.53–0.57 <0.001
All-cause mortality 0.55 0.53–0.57 <0.001
CV mortality 0.55 0.55–0.57 <0.001
Death from WHF 0.53 0.49–0.58 0.128
Sudden death 0.54 0.51–0.57 0.012
Coronary endpoint 0.54 0.51–0.56 0.003
Hospitalization, any cause 0.51 0.49–0.53 0.238
Hospitalization, CV cause 0.51 0.49–0.53 0.545
Hospitalization due to WHF 0.50 0.48–0.53 0.910
doi:10.1371/journal.pone.0133970.t004
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The non-linear associations between sFRP3 levels and outcomes in this study might also be
explained by inherent properties of Wnt signaling and the sFRP family of Wnt-modulators. A
recent report from our group has indicated that secretion of sFRP3 might be a compensatory
mechanism whereby the myocardium seeks to limit increased LV wall stress [16]. Thus, low
levels of sFRP3 could reflect inadequate response to pathological Wnt activity following ische-
mic injury and increased inflammation and high levels of sFRP3 might represent an overshoot
of repair mechanisms, which in itself might be deleterious. Patients with intermediate sFRP3
levels were characterized by lower CRP and higher LVEF suggesting that these patients were
healthier. Fig 3 illustrates the possible mechanism linking release of sFRP3 during LV wall
stress and a non-linear association with outcome. Also, others have reported biphasic effects of
sFRPs, potentially reflecting their complex mechanisms of action [10,27,28]. For instance,
Fig 2. Kaplan Meier plots showing the association between tertiles of sFRP3 and all-causemortality in the GISSI-HF-HF trial stratified according to
age and presence of ischemic heart disease. A. ischemic HF <70 years of ageB. ischemic HF >70 years of ageC. non-ischemic HF > 70 years D. all-
cause mortality in CORONA using cut-off derived from the GISSI-HF-HF trial.
doi:10.1371/journal.pone.0133970.g002
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extracellular sequestering of Wnt ligands and formation of inactive complexes with membrane
bound Frizzled receptors (Fzd-R) antagonizes Wnt signaling, whilst simultaneous binding to
ligand and receptor and sFRP-sFRP binding, titrating out each other’s activity, favor Wnt sig-
naling [10,27]. Also, Xavier et al. demonstrated that sFRP1either inhibits or enhances canonical
Wnt signaling depending on concentration and cellular context [28].
In the current study sFRP3 remained strongly associated with outcomes even after extensive
multivariable adjustment, including NT-proBNP, with stable HRs and relatively high Wald
scores. Adding sFRP3 to fully adjusted multivariable models produced highly significant NRIs
for all fatal outcomes, except for death fromWHF, as well as for the coronary endpoint.
Although analyses of sFRP3 in the current cohort suggests a significant association with
adverse prognosis, the use of the mid-tertile as a biomarker is, at least at present, not suitable
for clinical use. Nonetheless, our findings indicate involvement of soluble Wnt modulators in
the progression of clinical HF, with a potential complex interaction within the different mem-
bers of the Wnt family. It is conceivable that a greater understanding of Wnt signaling in HF
might provide us with new tools in the therapeutic armamentarium as both over-expression
and exogenous administration of sFRPs reduces morbidity and mortality in murine MI models
[12,14].
The present study examined multiple end points in a large HF population with a consider-
able number of events. However, for some subgroup analyses, including analyses of the end-
point Death fromWHF and the interaction of sFRP3 with rosuvastatin, there were relatively
few events and, therefore, these data should be interpreted cautiously. Our study was per-
formed in trial patients of60 years of age, with LV systolic dysfunction and ischemic heart
disease. Thus, the results may not apply to all patients with HF. There are a number of other
sFRP’s and other Wnt antagonists that future studies should evaluate as predictors of adverse
outcome in HF patients. The relatively poor association with established CV determinants, and
current medications in our study, may imply that Wnt signaling is relatively unaffected by state
of the art treatment regimens. Thus, the Wnt signaling pathway might represent an untapped
therapeutic potential for HF modulation.
In conclusion, mid-tertile serum concentrations of sFRP3 were associated with reduced
fatality in a large population of elderly patients with chronic systolic HF of ischemic origin.
Hazard ratios attributed to mid-tertile sFRP3 values remained significant and stable also when
Fig 3. Possible mechanism linking sFRP3 release during LV wall stress and non-linear association with survival. Increased wall stress [1] may
induce the release of sFRP3 from fibroblasts [2]. Depending on concentration of sFRP3 [3], this may lead to insufficient, balanced or excess inhibition of the
Wnt [4] in the presence of inflammation and lead to a non-linear association with survival [5].
doi:10.1371/journal.pone.0133970.g003
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accounting for established risk factors, including NT-proBNP and CRP. Although the use of
sFRP3 as a biomarker in clinical practice is premature, our findings support the involvement of
Wnt signaling in HF progression and suggest that this novel pathway might represent an as yet
unmodified mechanism in HF development.
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